HRP20192218T1 - Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene - Google Patents

Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene Download PDF

Info

Publication number
HRP20192218T1
HRP20192218T1 HRP20192218TT HRP20192218T HRP20192218T1 HR P20192218 T1 HRP20192218 T1 HR P20192218T1 HR P20192218T T HRP20192218T T HR P20192218TT HR P20192218 T HRP20192218 T HR P20192218T HR P20192218 T1 HRP20192218 T1 HR P20192218T1
Authority
HR
Croatia
Prior art keywords
human
gene
segments
mouse
light chain
Prior art date
Application number
HRP20192218TT
Other languages
English (en)
Croatian (hr)
Inventor
Lynn Macdonald
Cagan Gurer
Karolina A. Meagher
Sean Stevens
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HRP20192218T1 publication Critical patent/HRP20192218T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Central Heating Systems (AREA)
  • Housing For Livestock And Birds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20192218TT 2012-02-01 2013-02-01 Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene HRP20192218T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261593463P 2012-02-01 2012-02-01
US201261677538P 2012-07-31 2012-07-31
PCT/US2013/024295 WO2013116609A1 (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains
EP13704329.5A EP2809150B1 (en) 2012-02-01 2013-02-01 Humanized mice that express heavy chains containing vl domains

Publications (1)

Publication Number Publication Date
HRP20192218T1 true HRP20192218T1 (hr) 2020-03-06

Family

ID=47714588

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20192218TT HRP20192218T1 (hr) 2012-02-01 2013-02-01 Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene
HRP20210987TT HRP20210987T1 (hr) 2012-02-01 2021-06-23 Humanizirani glodavci koji eksprimiraju teške lance koji sadrže vl domene

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20210987TT HRP20210987T1 (hr) 2012-02-01 2021-06-23 Humanizirani glodavci koji eksprimiraju teške lance koji sadrže vl domene

Country Status (26)

Country Link
US (3) US20130212719A1 (enExample)
EP (3) EP3912465A1 (enExample)
JP (6) JP2015505477A (enExample)
KR (2) KR20140123983A (enExample)
CN (2) CN104202971B (enExample)
AU (3) AU2013204758B2 (enExample)
BR (1) BR112014018843B1 (enExample)
CA (1) CA2863175A1 (enExample)
CY (2) CY1122419T1 (enExample)
DK (2) DK3597038T3 (enExample)
ES (2) ES2870703T3 (enExample)
HR (2) HRP20192218T1 (enExample)
HU (2) HUE055610T2 (enExample)
IL (3) IL233827A0 (enExample)
LT (2) LT2809150T (enExample)
ME (1) ME03611B (enExample)
MX (2) MX373286B (enExample)
NZ (5) NZ793447A (enExample)
PL (2) PL3597038T3 (enExample)
PT (2) PT3597038T (enExample)
RS (2) RS59699B1 (enExample)
RU (2) RU2664185C2 (enExample)
SG (3) SG10201913428QA (enExample)
SI (2) SI3597038T1 (enExample)
SM (2) SMT202100401T1 (enExample)
WO (1) WO2013116609A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
IL315833A (en) 2010-08-02 2024-11-01 Regeneron Pharma Mice producing binding proteins containing VL regions
CN107602696B (zh) 2011-08-05 2022-05-13 瑞泽恩制药公司 人源化的通用轻链小鼠
EP2758535B1 (en) 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
SI2793567T1 (sl) 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši
EP3912465A1 (en) * 2012-02-01 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EP3912464A1 (en) 2012-06-12 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
PT2840892T (pt) 2013-02-20 2018-07-20 Regeneron Pharma Animais não humanos com sequências da cadeia pesada da imunoglobulina modificada
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3051942B1 (en) 2013-10-01 2020-09-02 Kymab Limited Animal models and therapeutic molecules
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CN107438622A (zh) * 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
ES2959608T3 (es) * 2015-04-03 2024-02-27 Dana Farber Cancer Inst Inc Composición y métodos de edición del genoma de células B
CA3017678A1 (en) * 2016-04-04 2017-10-12 Eth Zurich Mammalian cell line for protein production and library generation
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
WO2018183946A1 (en) * 2017-03-30 2018-10-04 Utah State University Transgenic silkworms expressing spider silk
AU2018381316B2 (en) * 2017-12-05 2025-06-26 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
RS66546B1 (sr) * 2018-03-24 2025-03-31 Regeneron Pharma Genetički modifikovani miševi ili pacovi za dobijanje terapeutskih antitela protiv peptid‑mhc kompleksa, postupci za njihovo dobijanje i upotrebe
IL318469A (en) * 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
IL303626A (en) 2020-12-16 2023-08-01 Regeneron Pharma Mice expressing humanized fc alpha receptors
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
CN114196626A (zh) * 2022-02-16 2022-03-18 北京国卫生物科技有限公司 脐带间充质干细胞及其分离培养扩增方法
CN118339300A (zh) * 2024-01-02 2024-07-12 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
WO2002012437A2 (en) * 2000-08-03 2002-02-14 Schooten Wim Van Production of humanized antibodies in transgenic animals
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
CN100526455C (zh) * 2001-12-21 2009-08-12 斯路姆-X股份有限公司 用于体外分离和培养具有种系传递能力的胚胎干细胞(es)细胞系的组合物
US20050246782A1 (en) * 2002-03-22 2005-11-03 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
CN1852925A (zh) * 2003-07-15 2006-10-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
WO2006047367A2 (en) * 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglubolin expression in non-human transgenic animals
WO2007117410A2 (en) * 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP2064325B1 (en) * 2006-09-01 2011-12-07 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
CA2697448C (en) * 2007-08-30 2019-06-11 The Burnet Institute Dendritic cell marker and uses thereof
TWI563002B (en) * 2007-09-26 2016-12-21 Chugai Pharmaceutical Co Ltd Antibody constant region mutant
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
CA2729095C (en) * 2008-06-27 2018-12-04 Merus B.V. Method for producing a transgenic murine mammal
US20100069262A1 (en) * 2008-08-29 2010-03-18 Symphogen A/S Method for Cloning Avian-Derived Antibodies
EP2394159B1 (en) * 2009-02-04 2018-09-26 Molecular Innovations Assays for detecting prorenin, and antibodies used therein
CN102638971B (zh) * 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CN105695415A (zh) * 2010-06-17 2016-06-22 科马布有限公司 动物模型及治疗分子
IL315833A (en) * 2010-08-02 2024-11-01 Regeneron Pharma Mice producing binding proteins containing VL regions
MX375115B (es) * 2011-02-25 2025-03-06 Regeneron Pharma Ratones de una desintegrina y metaloproteasa 6 (adam6).
CN107602696B (zh) * 2011-08-05 2022-05-13 瑞泽恩制药公司 人源化的通用轻链小鼠
SI2793567T1 (sl) * 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši
EP3912465A1 (en) * 2012-02-01 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
EP3912464A1 (en) * 2012-06-12 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
PL4082334T3 (pl) * 2016-11-04 2025-08-11 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż człowiek posiadające zmodyfikowane locus łańcucha lekkiego lambda immunoglobuliny

Also Published As

Publication number Publication date
HRP20210987T1 (hr) 2021-09-17
EP3597038A1 (en) 2020-01-22
RS59699B1 (sr) 2020-01-31
JP6942757B2 (ja) 2021-09-29
IL233827A0 (en) 2014-09-30
CN106117364B (zh) 2021-08-31
ME03611B (me) 2020-07-20
PT2809150T (pt) 2019-12-09
AU2015246154B2 (en) 2017-11-23
RS62023B1 (sr) 2021-07-30
NZ719228A (en) 2022-08-26
SG10201913428QA (en) 2020-03-30
BR112014018843A2 (pt) 2017-07-04
IL261280A (en) 2018-10-31
JP7187615B2 (ja) 2022-12-12
HUE055610T2 (hu) 2021-12-28
MX2019002517A (es) 2019-06-17
CA2863175A1 (en) 2013-08-08
JP2019170395A (ja) 2019-10-10
MX2020003491A (es) 2022-10-25
SG10201606256TA (en) 2016-09-29
EP3597038B1 (en) 2021-04-21
BR112014018843A8 (pt) 2019-01-29
KR20190006029A (ko) 2019-01-16
CN104202971B (zh) 2016-07-06
HK1202771A1 (en) 2015-10-09
RU2664185C2 (ru) 2018-08-15
US20170094955A1 (en) 2017-04-06
JP6698718B2 (ja) 2020-05-27
IL261280B (en) 2019-08-29
JP2015505477A (ja) 2015-02-23
IL268675A (en) 2019-10-31
BR112014018843B1 (pt) 2024-02-20
NZ793447A (en) 2024-05-31
SMT201900685T1 (it) 2020-01-14
MX373286B (es) 2020-05-20
SI2809150T1 (sl) 2019-11-29
US20210368751A1 (en) 2021-12-02
EP2809150A1 (en) 2014-12-10
SMT202100401T1 (it) 2021-09-14
AU2015246154A1 (en) 2015-11-12
LT2809150T (lt) 2019-10-25
CN106117364A (zh) 2016-11-16
RU2014133653A (ru) 2016-03-20
EP2809150B1 (en) 2019-09-18
IL268675B (en) 2020-11-30
DK3597038T3 (da) 2021-06-28
PT3597038T (pt) 2021-05-10
NZ810648A (en) 2025-11-28
NZ627977A (en) 2016-06-24
AU2013204758A1 (en) 2013-08-15
SG11201404477YA (en) 2014-08-28
PL2809150T3 (pl) 2020-04-30
RU2018122695A (ru) 2019-03-06
PL3597038T3 (pl) 2021-11-08
RU2018122695A3 (enExample) 2021-10-06
JP2021137030A (ja) 2021-09-16
KR20140123983A (ko) 2014-10-23
LT3597038T (lt) 2021-05-25
AU2017251848B2 (en) 2020-02-20
JP2023014242A (ja) 2023-01-26
ES2753774T3 (es) 2020-04-14
CN104202971A (zh) 2014-12-10
SI3597038T1 (sl) 2021-07-30
AU2017251848A1 (en) 2017-11-16
RU2770016C2 (ru) 2022-04-14
JP7525579B2 (ja) 2024-07-30
EP3912465A1 (en) 2021-11-24
CY1122419T1 (el) 2021-01-27
JP2018075041A (ja) 2018-05-17
HUE046744T2 (hu) 2020-03-30
AU2013204758B2 (en) 2015-07-23
DK2809150T3 (da) 2019-12-09
US20130212719A1 (en) 2013-08-15
ES2870703T3 (es) 2021-10-27
CY1124361T1 (el) 2022-07-22
NZ734504A (en) 2022-10-28
JP2023168590A (ja) 2023-11-24
WO2013116609A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
HRP20192218T1 (hr) Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene
HRP20241480T1 (hr) Humanizirani miševi univerzalnog lakog lanca
JP2015505477A5 (enExample)
HRP20190897T1 (hr) Laki lanac humaniziranih miševa
HRP20171357T1 (hr) Ograničeni teški lanac imunoglobulina u miševa
JP2015502177A5 (enExample)
RU2013102595A (ru) Мыши, экспрессирующие гибридную легкую цепь иммуноглобулина
WO2012145469A8 (en) Human monoclonal antibodies specific for glypican-3 and use thereof
HRP20170322T1 (hr) Miševi koji stvaraju vl vezne proteine
JP2014110814A5 (enExample)
HRP20192311T4 (hr) Adam6 miševi
HRP20230490T1 (hr) Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina
HRP20191680T1 (hr) Neljudske životinje koje izražavaju antitijela sa zajedničkim lakim lancem
NZ711451A (en) Anti-c5 antibodies having improved pharmacokinetics
HRP20191333T1 (hr) Glodavci koji izražavaju sekvence imunoglobulina osjetljive na ph vrijednost
JP2014524243A5 (enExample)
HRP20171193T1 (hr) Proizvodnja vezivnih molekula
JOP20180042A1 (ar) نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
FI4082334T3 (fi) Muokatun immunoglobuliinin lambda-kevytketjun lokuksen omaavia ei-humaaneja eläimiä
HK1250038A1 (zh) 选择结合抗原的轻链可变区的非人动物
BR112016021572A2 (pt) Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
HRP20220081T1 (hr) Bcma i cd3 bispecifična t stanica koja uključuje konstrukte protutijela
HK1218550A1 (zh) 常見輕鏈小鼠
HRP20240774T1 (hr) Anti-il-33 antitijela i njihove upotrebe
RU2019121863A (ru) Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения